Back To Main Site
Business News
Miliband pledge on tax avoidance
BBC News - Business, May 19th, 2013
Labour leader Ed Miliband says he will write new rules to tackle corporate tax avoidance if he wins the next election, even without international agreement.
Bank governor in Help to Buy warning
BBC News - Business, May 19th, 2013
The outgoing Bank of England governor warns a government plan to boost the housing market with part-mortgage guarantees has no long-term place.
Should we all be more psychopathic?
BBC News - Business, May 18th, 2013
Should we all be more psychopathic at work?
Contactless ‘charging errors’ at M&S
BBC News - Business, May 18th, 2013
Some Marks and Spencer customers say its contactless payment terminals have taken cash from cards other than the ones intended for payment.
Ofcom plans simplified phone numbers
BBC News - Business, May 18th, 2013
Some people are "put off" making important calls because of confusion over the amount they will be charged, according to the telecoms regulator.
Company Profile
| Name: | Shire ltd |  |
|---|---|---|
| Address: | Hampshire International Business Park, Chineham, Basingstoke, RG24 8EP, UK | |
| Website: | www.shire.com | |
| Sector: | Healthcare | |
| Industry: | Biotechnology | |
| Summary: | Shire Ltd., formerly Shire plc, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. In June 2007, the Company received an approvable letter from the United States Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a non-stimulant selective alpha-2A-receptor agonist. On November 7, 2007, Shire entered into a license agreement with Amicus Therapeutics, Inc. (Amicus), under which it received the rights to three compounds, PLICERA, AMIGAL and AT2220, in markets outside the United States. In April 2008, Shire announced the acquisition of arylsulfatase-A (ASA), an enzyme replacement therapy (ERT) in Phase I-II clinical trials for metachromatic leukodystrophy (MLD) from the Danish company, Zymenex A/S. | |
Company Information
| 2,050.50 | Open: | 2,047.00 | High: | 2,055.00 | Mkt Cap: | 11.38B | Ex-Div: | - |
|---|---|---|---|---|---|---|---|---|
| Bid: | 2,050.00 | Low: | 2,030.00 | P/E: | - | Shares: | 554.19M | |
-3.50 (-0.17%) |
Ask: | 2,051.00 | 52Wk High: | 2,173.00 | EPS: | - | Last Trade: | 2,050.00 |
| Delayed: 16:29 BST | Vol: | 978.41k | 52Wk Low: | 1,682.00 |
Loading…
Related Stocks
| Name | Last 50d | Current | Change | Mkt Cap | Volume |
|---|---|---|---|---|---|
| Vindon Healthcare PLC | - | - | 8.89M | 1.37k | |
| ViaLogy PLC | 1.20 | 0.00% | 12.47M | 2.83M | |
| Verona Pharma PLC | 2.48 | 2.06% | 8.15M | 1.03M | |
| Vectura Group PLC | 90.38 | -3.34% | 312.61M | 574.09k | |
| ValiRx PLC | - | - | 7.96M | 3.91M | |
| Ultrasis PLC | - | - | 4.69M | 13.37k | |
| Tristel PLC | - | - | 9.00M | 93.53k | |
| Taihua PLC | - | - | 3.47M | 35.00k | |
| Summit Corporation PLC | 4.13 | -1.20% | 14.78M | 825.43k | |
| Smith & Nephew PLC | 775.50 | -1.02% | 7.10B | 1.70M | |
| Sinclair IS Pharma PLC | 28.13 | 0.90% | 121.23M | 484.89k | |
| Silvermere Energy PLC | 2.25 | 0.00% | 647.72k | 0 | |
| Shire PLC | 2,050.50 | -0.17% | 11.38B | 978.41k | |
| Sareum Holdings PLC | 0.85 | 0.00% | 12.93M | 9.49M | |
| Renovo Group PLC | - | - | 28.98M | 2.00k | |
| Reneuron Group PLC | 2.44 | -9.48% | 20.84M | 1.90M | |
| Proteome Sciences PLC | 69.50 | 7.34% | 124.64M | 716.75k | |
| Prime People PLC | 55.00 | 0.00% | 6.54M | 0 | |
| Plethora Solutions Holdings Plc | 1.55 | 0.00% | 5.36M | 40.78k | |
| Plant Health Care PLC | 85.50 | 1.18% | 59.60M | 9.12k | |
| Oxford Pharmascience Group PLC | - | - | 35.23M | 2.12M | |
| Oxford Biomedica PLC | - | - | 32.22M | 851.05k | |
| Omega Diagnostics Group PLC | 18.50 | -1.99% | 16.08M | 280.79k | |
| Mediwatch PLC | 2.50 | -4.76% | 3.70M | 274.63k | |
| Mears Group Plc | 376.00 | 0.67% | 367.50M | 19.92k | |
| MDY Healthcare PLC | 9.50 | 0.00% | 2.39M | 0 | |
| Lidco Group PLC | - | 0.00% | 21.56M | 0 | |
| Kedco PLC | - | - | 8.95M | 40.00k | |
| Immunodiagnostic Systems Holdings PLC | 449.50 | 2.28% | 126.01M | 62.68k | |
| ImmuPharma PLC | - | 0.00% | 29.35M | 203.64k | |
| Hydrodec Group | 11.00 | 1.15% | 45.94M | 444.90k | |
| Hikma Pharmaceuticals PLC | 976.00 | -2.40% | 1.97B | 278.78k | |
| Healthcare Locums PLC | - | - | 6.44M | 35.75k | |
| GlaxoSmithKline PLC | 1,711.00 | 0.20% | 84.11B | 7.24M | |
| GW Pharmaceuticals PLC | 49.00 | 1.29% | 84.84M | 71.67k | |
| Futura Medical PLC | - | - | 55.79M | 100.01k | |
| Epistem Holdings PLC | - | 0.00% | 53.97M | 0 | |
| Deltex Medical Group PLC | - | - | 23.22M | 166.85k | |
| Dechra Pharmaceuticals PLC | 716.25 | 1.24% | 616.34M | 43.64k | |
| Consort Medical PLC | 779.00 | -0.76% | 229.28M | 9.02k | |
| Caretech Holdings PLC | 172.50 | 0.88% | 87.54M | 19.38k | |
| CPL Resources PLC | 257.50 | - | 132.11M | 0 | |
| BTG PLC | 355.25 | 0.81% | 1.16B | 647.29k | |
| Astrazeneca PLC | 3,379.25 | -0.30% | 42.36B | 2.20M | |
| Assura Group Limited | 38.25 | 5.52% | 191.96M | 539.18k | |
| Aortech International | - | - | 3.00M | 400 | |
| Alliance Pharma PLC | 36.63 | 0.69% | 90.40M | 322.68k | |
| Allergy Therapeutics PLC | 10.13 | 0.00% | 42.01M | 0 | |
| Alexander David Investments PLC | 0.13 | 0.00% | 598.34k | 0 | |
| Akers Biosciences Inc | - | - | 3.28M | 89.93k | |
| Advanced Medical Solutions Group PLC | 77.25 | 0.32% | 157.57M | 311.57k | |
| Abcam PLC | 451.50 | 0.11% | 898.96M | 92.47k |